Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07677293 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Peking University
118 trials monitored
See 4 trials at risk
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
This study is a randomized, controlled, open-label phase III clinical trial, aims to compare the efficacy and safety of Retlirafusp alfa injection plus CAPOX versus the investigator's choice of anti-PD-1 antibody plus CAPOX as first-line treatment in patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) with liver metastases
Trial Details
NCT Number NCT07677293
Lead Sponsor Peking University
Conditions
(from sponsor)		 Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Enrollment 332 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov